Forte Biosciences Inc. (FBRX)
7.75
-1.35 (-14.84%)
At close: Mar 03, 2025, 3:59 PM
7.68
-0.90%
After-hours: Mar 03, 2025, 04:00 PM EST
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.
Forte Biosciences Inc.
| Country | United States |
| IPO Date | Apr 13, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive Dallas, Texas United States | |
| Website | https://www.fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G1094 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President & Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Christopher Roenfeldt | Chief Operating Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
| Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 07, 2025 | S-8 | Filing |